Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF4968 - Provider product page
- Provider
- R&D Systems
- Product name
- Human CLEC14A Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human CLEC14A in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human (rh) CLEC1, rhCLEC2, rhCLEC3B, and rhCLEC10A is observed.
- Reactivity
- Human
- Host
- Sheep
- Conjugate
- Unconjugated
- Antigen sequence
Q86T13- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis.
Sprouting angiogenesis is regulated by shedding of the C-type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid-like 2 protein (RHBDL2).
Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth.
Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.
Identification and angiogenic role of the novel tumor endothelial marker CLEC14A.
Kim TK, Park CS, Jang J, Kim MR, Na HJ, Lee K, Kim HJ, Heo K, Yoo BC, Kim YM, Lee JW, Kim SJ, Kim ES, Kim DY, Cha K, Lee TG, Lee S
Molecular oncology 2018 Mar;12(3):356-372
Molecular oncology 2018 Mar;12(3):356-372
CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis.
Jang J, Kim MR, Kim TK, Lee WR, Kim JH, Heo K, Lee S
Scientific reports 2017 Sep 6;7(1):10666
Scientific reports 2017 Sep 6;7(1):10666
Sprouting angiogenesis is regulated by shedding of the C-type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid-like 2 protein (RHBDL2).
Noy PJ, Swain RK, Khan K, Lodhia P, Bicknell R
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2016 Jun;30(6):2311-23
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2016 Jun;30(6):2311-23
Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth.
Noy PJ, Lodhia P, Khan K, Zhuang X, Ward DG, Verissimo AR, Bacon A, Bicknell R
Oncogene 2015 Nov 19;34(47):5821-31
Oncogene 2015 Nov 19;34(47):5821-31
Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.
Ki MK, Jeoung MH, Choi JR, Rho SS, Kwon YG, Shim H, Chung J, Hong HJ, Song BD, Lee S
Oncogene 2013 Nov 28;32(48):5449-57
Oncogene 2013 Nov 28;32(48):5449-57
Identification and angiogenic role of the novel tumor endothelial marker CLEC14A.
Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S, Beesley JF, Herbert JM, Sheldon H, Andre M, Sanderson S, Glen K, Luu NT, McGettrick HM, Antczak P, Falciani F, Nash GB, Nagy ZS, Bicknell R
Oncogene 2012 Jan 19;31(3):293-305
Oncogene 2012 Jan 19;31(3):293-305
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- CLEC14A in HUVEC Human Cells. CLEC14A was detected in immersion fixed HUVEC human umbilical vein endothelial cells using Sheep Anti-Human CLEC14A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4968) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- CLEC14A in Human Breast Cancer Tissue. CLEC14A was detected in formalin fixed paraffin-embedded sections of human breast cancer tissue using Sheep Anti-Human CLEC14A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4968) at 1.7 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Universal (Catalog # CTS015). Tissue was stained using the Anti-Sheep HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS019) and counterstained with hematoxylin (blue). Specific staining was localized to endothelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Clec-14A in HUVEC Human Cells by Flow Cytometry. HUVEC human umbilical vein endothelial cells were stained with Sheep Anti-Human CLEC14A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4968, filled histogram) or isotype control antibody (Catalog # 5-001-A, open histogram), followed by Phycoerythrin-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # F0126).
